Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions DMARDs & Immunosuppressives interstitial lung disease (ILD) systemic sclerosis (SSc) systemic sclerosis-associated ILD tocilizumab Source Type: research